MA47729A - Inhibiteurs de bêta-sécrétase - Google Patents

Inhibiteurs de bêta-sécrétase

Info

Publication number
MA47729A
MA47729A MA047729A MA47729A MA47729A MA 47729 A MA47729 A MA 47729A MA 047729 A MA047729 A MA 047729A MA 47729 A MA47729 A MA 47729A MA 47729 A MA47729 A MA 47729A
Authority
MA
Morocco
Prior art keywords
beta
secretase inhibitors
secretase
inhibitors
Prior art date
Application number
MA047729A
Other languages
English (en)
Inventor
Sathesh Pangala Bhat
Henricus Jacobus Maria Gijsen
Daniel Oehlrich
Den Keybus Frans Alfons Maria Van
Ann Marleen Vos
Karl Shawn Watts
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MA47729A publication Critical patent/MA47729A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MA047729A 2017-03-07 2018-03-06 Inhibiteurs de bêta-sécrétase MA47729A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762468052P 2017-03-07 2017-03-07
EP17189762 2017-09-07

Publications (1)

Publication Number Publication Date
MA47729A true MA47729A (fr) 2020-01-15

Family

ID=61616993

Family Applications (1)

Application Number Title Priority Date Filing Date
MA047729A MA47729A (fr) 2017-03-07 2018-03-06 Inhibiteurs de bêta-sécrétase

Country Status (9)

Country Link
US (1) US20200010482A1 (fr)
EP (1) EP3592750A1 (fr)
JP (1) JP2020509068A (fr)
KR (1) KR20190126345A (fr)
CN (1) CN110418793A (fr)
AU (1) AU2018229721A1 (fr)
CA (1) CA3051764A1 (fr)
MA (1) MA47729A (fr)
MX (1) MX2019010649A (fr)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR077277A1 (es) * 2009-07-09 2011-08-17 Lilly Co Eli Compuestos de biciclo (1,3)tiazin-2-amina formulacion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de la enfermedad de alzheimer
US20120245155A1 (en) * 2009-12-11 2012-09-27 Shionogi & Co., Ltd. Fused heterocyclic compound having amino group
WO2014059185A1 (fr) * 2012-10-12 2014-04-17 Amgen Inc. Composés amino-dihydrothiazine et amino-dioxydo dihydrothiazine en tant qu'antagonistes de bêta-sécrétase et procédés d'utilisation

Also Published As

Publication number Publication date
US20200010482A1 (en) 2020-01-09
AU2018229721A1 (en) 2019-08-15
KR20190126345A (ko) 2019-11-11
CN110418793A (zh) 2019-11-05
JP2020509068A (ja) 2020-03-26
CA3051764A1 (fr) 2018-09-13
MX2019010649A (es) 2019-10-21
EP3592750A1 (fr) 2020-01-15

Similar Documents

Publication Publication Date Title
IL283639A (en) Kif18a inhibitors
MA54550A (fr) Inhibiteurs de kif18a
IL269196A (en) Novel inhibitors
EP3541932A4 (fr) Inhibiteurs de crispr-cas9
DK3612525T3 (da) Pd-1-/pd-l1-inhibitorer
MA52812A (fr) Inhibiteurs de sarm1
DK3497103T3 (da) Pyridopyrimdinon-cdk2/4/6-inhibitorer
DK3571192T3 (da) Jak1-selektive inhibitorer
DK3442972T3 (da) Bromdomænehæmmere
EP3347008A4 (fr) Inhibiteurs de bêta-lactamases
LT3303334T (lt) Tirozinkinazės inhibitoriai
DK3681884T3 (da) Rad51-inhibitorer
MA46855A (fr) Inhibiteurs de magl
EP3313828A4 (fr) Inhibiteurs de métallo-bêta-lactamases
CU20160125A7 (es) Inhibidores de diacilglicerol aciltransferasa 2
MA52813A (fr) Inhibiteurs de sarm1
MA46857A (fr) Inhibiteurs de magl
EP3817736A4 (fr) Inhibiteurs de pikfyve
MA46860A (fr) Inhibiteurs de magl
EP3609882A4 (fr) Inhibiteurs hétérocycliques de pcsk9
EP3801499A4 (fr) Inhibiteurs de sarm1
DK3630744T3 (da) Pyrazol-magl-inhibitorer
EP3720436A4 (fr) Inhibiteurs de tubuline
MA43367A (fr) Inhibiteurs de métallo-bêta-lactamases
EP3600301A4 (fr) Inhibiteurs de kdm4